1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials
  4. >>Diversity & Inclusion

COVID-Era Trial Flexibilities, Equity Focus, Could Be Used To Reshape Cancer Study Enrollment

 
• By Sarah Karlin-Smith

US FDA is open to keeping COVID-necessitated trial changes that may have had unexpected benefits. The agency is also looking at building on pandemic’s focus on health disparities and inequities to push for more generalizable and inclusive clinical trial designs.

older woman stretching
FDA may allow trials to keep pandemic flexibilities to increase study diversity • Source: Alamy

Clinical trial operational and design changes made due to the COVID-19 pandemic are likely to be harnessed to improve the diversity and generalizability of studies long after the current infectious disease outbreak has subsided, US Food and Drug Administration officials indicated.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Diversity & Inclusion

More from Clinical Trials